Safety and Antiviral Activity of EGFR Inhibition by Erlotinib in Chronic Hepatitis C Patients: A Phase Ib Randomized Controlled Trial

Significant hepatocellular carcinoma (HCC) risk persists after chronic hepatitis C (CHC) cure. Preclinical studies have shown that erlotinib, an oral epidermal growth factor receptor (EGFR) inhibitor, has an antiviral activity and HCC chemopreventive effect. Erlotinib is metabolized in the liver, an...

Descripción completa

Detalles Bibliográficos
Autores principales: Saviano, Antonio, Habersetzer, François, Lupberger, Joachim, Simo-Noumbissie, Pauline, Schuster, Catherine, Doffoël, Michel, Schmidt-Mutter, Catherine, Baumert, Thomas F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9236598/
https://www.ncbi.nlm.nih.gov/pubmed/35363627
http://dx.doi.org/10.14309/ctg.0000000000000492

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9236598/
https://www.ncbi.nlm.nih.gov/pubmed/35363627
http://dx.doi.org/10.14309/ctg.0000000000000492

Ejemplares similares